**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 69240

**Manuscript Type:** LETTER TO THE EDITOR

**Microarray analysis to explore the effect of *CXCL12* isoforms in a pancreatic pre-tumor cell model**

Miao YD *et al*. *CXCL12* isoforms in a pancreatic pre-tumor cell model

Yan-Dong Miao, Jiang-Tao Wang, Xiao-Long Tang, Deng-Hai Mi

**Yan-Dong Miao, Jiang-Tao Wang, Xiao-Long Tang, Deng-Hai Mi,** The First Clinical Medical College, Lanzhou University, Lanzhou 730000, Gansu Province, China

**Deng-Hai Mi,** Dean's office, Gansu Academy of Traditional Chinese Medicine, Lanzhou 730000, Gansu Province, China

**Author contributions:** Mi DH and Miao YD designed the research; Miao YD wrote this comment; Wang JT and Tang XL made academic advice; Mi DH reviewed this manuscript; all authors approved the final manuscript.

**Corresponding author: Yan-Dong Miao, MD, Doctor,** The First Clinical Medical College, Lanzhou University, No. 1 Donggang West Road, Chengguan District, Lanzhou 730000, Gansu Province, China. miaoyd19@lzu.edu.cn

**Received:** June 22, 2021

**Revised:** July 6, 2021

**Accepted: December 2, 2021**

**Published online:**

**Abstract**

*CXCL12* expression was significantly lower in tumor samples than in corresponding normal samples. *CXCL12* expression was significantly positively related to the infiltration levels of T cells, dendritic cells (DCs), immature DCs, cytotoxic cells, Tfh cells, mast cells, B cells, Th1 cells, natural killer (NK) cells, pDCs, neutrophils, and T helper cells (Spearman correlation coefficient > 0.5, *P* < 0.001) and negatively correlated with the infiltration level of NK CD56bright cells. In addition, pancreatic hTERT-HPNE cells treated with three diverse *CXCL12* isoforms exhibited changes mainly in the regulation of the epithelial-mesenchymal transition activation pathway.

**Key Words:** *CXCL12*; Pancreatic cancer; Splicing isoforms; Bioinformatics analysis; Tumor microenvironment; Pathway

Miao YD, Wang JT, Tang XL, Mi DH. Microarray analysis to explore the effect of *CXCL12* isoforms in a pancreatic pre-tumor cell model. *World J Gastroenterol* 2021; In press

**Core Tip:** *CXCL12* expression was significantly lower in tumor samples than in normal samples. *CXCL12* expression was significantly positively associated with the infiltration levels of 12 immune cells, especially T cells, which may encourage further exploration of the effect of *CXCL12* in pancreatic ductal adenocarcinoma immunotherapy. In addition, treating pancreatic hTERT-HPNE cells with three diverse *CXCL12* isoforms mainly affected the regulation of the epithelial-mesenchymal transition activation pathway.

**TO THE EDITOR**

We read with interest the article by Cecati *et al*[1]. They investigated the specific roles of α, β, and γ *CXCL12* isoforms in pancreatic ductal adenocarcinoma (PDCA) onset by microarray analysis of hTERT-HPNE cells cured by three diverse isoforms of *CXCL12*, which indicated that *CXCL12* isoforms have different roles in PDAC pathogenesis.

We appreciate the unique perspective provided by the authors’ exploration of the roles of the different isomers of *CXCL12* in PDAC. However, the results might be made more meaningful if the authors built on this by presenting the differential expression of *CXCL12* in normal and tumor tissues of PDCA as a whole, such as through a bioinformatics analysis of PDCA cases in The Cancer Genome Atlas (TCGA) database or their own data. We discovered that the *CXCL12* expression was significantly lower in tumor samples than in normal samples (Figure 1A). Detailed statistical results are described in Table 1.

The tumor microenvironment (TME), mediated by interactions between stromal cells and pancreatic epithelial/carcinoma cells, is essential for PDCA progression and has been associated with failure of chemotherapy, radiotherapy, and immunotherapy[2]. The formation of the microenvironment requires interactions between pancreatic cancer cells and stromal cells. A pancreatic cancer microenvironment composition that favors demyelination and immunosuppression is related to poor prognosis[3-5]. Although immunotherapy has transformed cancer therapy, patients with PDCA rarely respond to these regimens, and this failure is attributed to poor infiltration and activation of T cells in the TME. We found that *CXCL12* expression was positively correlated with the level of infiltration of 22 immune cells, especially T cells (Figure 1B and C), which may encourage further exploration of the effect of *CXCL12* in PDCA immunotherapy. Detailed information on the correlation between *CXCL12* expression and immune cell infiltration is shown in Table 2.

We agree with Cecati *et al*[1]*,* who reported that all *CXCL12* isoforms influenced cell migration, adhesion, and cytoskeleton-associated gene expression. In our study, we found that treating pancreatic hTERT-HPNE cells with three diverse *CXCL12* isoforms mainly affects the regulation of the EMT activation pathway (Figure 1D-F), which confirms that the work done by Cecati *et al*[1] is worthy of recognition and that our findings can be a supplement to their study. In the future, we should investigate the role played by *CXCL12* in the PDCA immune microenvironment in depth.

***Statistical analysis***

Software: R (version 3.6.3) was used to perform statistical analysis and visualization results. Differential expression of *CCXL12* between pancreatic cancer tissues and normal tissues was adopted by the Wilcoxon rank-sum test and visualized results using R-package "ggplot2". Immune cell algorithm: ssGSEA (built-in algorithm of GSVA package[6]). Correlation test using Spearman's correlation coefficient. Pathway analysis was performed by the online tool GSCALite (http://bioinfo.life.hust.edu.cn/web/GSCALite/)[7].

**ACKNOWLEDGEMENTS**

Yan-Dong Miao would like to give particularly grateful to Wu-Xia Quan for her care, patience, and support over the past years and for her contributions to this study.

**REFERENCES**

1 **Cecati M**, Giulietti M, Righetti A, Sabanovic B, Piva F. Effects of CXCL12 isoforms in a pancreatic pre-tumour cellular model: Microarray analysis. *World J Gastroenterol* 2021; **27**: 1616-1629 [PMID: 33958847 DOI: 10.3748/wjg.v27.i15.1616]

2 **Ren B**, Cui M, Yang G, Wang H, Feng M, You L, Zhao Y. Tumor microenvironment participates in metastasis of pancreatic cancer. *Mol Cancer* 2018; **17**: 108 [PMID: 30060755 DOI: 10.1186/s12943-018-0858-1]

3 **Thomas D**, Radhakrishnan P. Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis. *Mol Cancer* 2019; **18**: 14 [PMID: 30665410 DOI: 10.1186/s12943-018-0927-5]

4 **Vivian J**, Rao AA, Nothaft FA, Ketchum C, Armstrong J, Novak A, Pfeil J, Narkizian J, Deran AD, Musselman-Brown A, Schmidt H, Amstutz P, Craft B, Goldman M, Rosenbloom K, Cline M, O'Connor B, Hanna M, Birger C, Kent WJ, Patterson DA, Joseph AD, Zhu J, Zaranek S, Getz G, Haussler D, Paten B. Toil enables reproducible, open source, big biomedical data analyses. *Nat Biotechnol* 2017; **35**: 314-316 [PMID: 28398314 DOI: 10.1038/nbt.3772]

5 **Bindea G**, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, Bruneval P, Fridman WH, Becker C, Pagès F, Speicher MR, Trajanoski Z, Galon J. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. *Immunity* 2013; **39**: 782-795 [PMID: 24138885 DOI: 10.1016/j.immuni.2013.10.003]

6 **Hänzelmann S**, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. *BMC Bioinformatics* 2013; **14**: 7 [PMID: 23323831 DOI: 10.1186/1471-2105-14-7]

7 **Liu CJ**, Hu FF, Xia MX, Han L, Zhang Q, Guo AY. GSCALite: a web server for gene set cancer analysis. *Bioinformatics* 2018; **34**: 3771-3772 [PMID: 29790900 DOI: 10.1093/bioinformatics/bty411]

**Footnotes**

**Conflict-of-interest statement:** No conflict of interest associated with any of the senior authors or other coauthors contributed their efforts in this manuscript.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** June 22, 2021

**First decision:** July 4, 2021

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Nagaraju GP **S-Editor:** Fan JR **L-Editor:** A **P-Editor:** Fan JR

**Figure Legends**

 

**Figure 1 The effect of *CXCL12* in the development of pancreatic ductal adenocarcinoma.** A: The differential *CXCL12* expression in pancreatic ductal adenocarcinoma (PDCA) and normal samples. The expression level of *CXCL12* in tumor tissues is indicated in orange, and that in normal tissues is indicated in purple. Data source: UCSC XENA (https://xenabrowser.net/datapages/) RNAseq data in TPM format for The Cancer Genome Atlas (TCGA) and GTEx processed uniformly through the Toil process[4]. PAAD (pancreatic cancer) data were extracted from TCGA, and corresponding normal sample data were from GTEx. Significance markers: NS, *P* ≥ 0.05, a*P* < 0.05, b*P* < 0.01, c*P* < 0.001; B: The expression level of *CXCL12* and its relationship to 24 immune cell infiltration levels in PDCA. Data source: RNAseq data and clinical data in level 3 HTSeq-FPKM format from the TCGA (https://portal.gdc.cancer.gov/) PAAD (pancreatic cancer) project. Data filtering: Removal of paraneoplastic tissue; C: The expression level of *CXCL12* and its relationship to the T cell infiltration level in PDCA; D and E: Pathway analysis of differentially expressed genes under all treatment conditions (α, β, and γ *CXCL12* isoforms); D: *CXCL12* α isoform *vs* control; E: *CXCL12* β isoform *vs* control; F: *CXCL12* γ isoform *vs* control.

**Table 1 Detailed statistical results of *CXCL12* differential expression analysis in pancreatic ductal adenocarcinoma (mean ± SD)**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Group** | **Number** | **Minimum** | **Maximum** | **Median** |  **IQR** | **Lower quartile** | **Upper quartile** | **Mean** |  | **SE** |
| Normal | 171 | 0 | 7.296 | 5.433 | 0.756 | 5.028 | 5.784 | 5.403 | 0.88 | 0.067 |
| Tumor | 179 | 1.333 | 7.629 | 4.632 | 2.134 | 3.727 | 5.861 | 4.803 | 1.445 | 0.108 |

IQR: Interquartile distance; SE: Standard error.

**Table 2 Detailed information on the correlation between *CXCL12* expression and immune cell infiltration**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Gene** | **Cell** | **Correlation coefficient (Pearson)** | ***P* value (Pearson)** | **Correlation coefficient (Spearman)** | ***P* value (Spearman)** |
| *CXCL12* | aDC | 0.355 | < 0.001 | 0.350 | < 0.001 |
| *CXCL12* | B cells | 0.614 | < 0.001 | 0.610 | < 0.001 |
| *CXCL12* | CD8 T cells | 0.508 | < 0.001 | 0.491 | < 0.001 |
| *CXCL12* | Cytotoxic cells | 0.674 | < 0.001 | 0.650 | < 0.001 |
| *CXCL12* | DC | 0.668 | < 0.001 | 0.658 | < 0.001 |
| *CXCL12* | Eosinophils | 0.488 | < 0.001 | 0.480 | < 0.001 |
| *CXCL12* | iDC | 0.639 | < 0.001 | 0.654 | < 0.001 |
| *CXCL12* | Macrophages | 0.488 | < 0.001 | 0.487 | < 0.001 |
| *CXCL12* | Mast cells | 0.635 | < 0.001 | 0.634 | < 0.001 |
| *CXCL12* | Neutrophils | 0.554 | < 0.001 | 0.535 | < 0.001 |
| *CXCL12* | NK CD56bright cells | -0.411 | < 0.001 | -0.397 | < 0.001 |
| *CXCL12* | NK CD56dim cells | 0.376 | < 0.001 | 0.369 | < 0.001 |
| *CXCL12* | NK cells | 0.566 | < 0.001 | 0.560 | < 0.001 |
| *CXCL12* | pDC | 0.558 | < 0.001 | 0.546 | < 0.001 |
| *CXCL12* | T cells | 0.682 | < 0.001 | 0.666 | < 0.001 |
| *CXCL12* | T helper cells | 0.511 | < 0.001 | 0.504 | < 0.001 |
| *CXCL12* | Tcm | 0.337 | < 0.001 | 0.285 | < 0.001 |
| *CXCL12* | Tem | 0.483 | < 0.001 | 0.481 | < 0.001 |
| *CXCL12* | TFH | 0.668 | < 0.001 | 0.645 | < 0.001 |
| *CXCL12* | Tgd | 0.364 | < 0.001 | 0.472 | < 0.001 |
| *CXCL12* | Th1 cells | 0.594 | < 0.001 | 0.605 | < 0.001 |
| *CXCL12* | Th17 cells | 0.057 | 0.453 | 0.065 | 0.387 |
| *CXCL12* | Th2 cells | 0.069 | 0.357 | 0.032 | 0.675 |
| *CXCL12* | TReg | 0.493 | < 0.001 | 0.482 | < 0.001 |

aDC: Activated DC; DC: Dendritic cells; iDC: immature DC; pDC: Plasmacytoid DC; Tfh: T follicular helper; Tgd: T gamma delta; NK: Natural killer.